Insider Transactions in Q2 2025 at Day One Biopharmaceuticals, Inc. (DAWN)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 16
2025
|
Lauren Merendino Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,927
-10.05%
|
$23,562
$6.26 P/Share
|
|
May 16
2025
|
Charles N York Ii COO, CFO AND SECRETARY |
SELL
Open market or private sale
|
Direct |
4,282
-1.59%
|
$25,692
$6.26 P/Share
|
|
May 16
2025
|
Adam Dubow GENERAL COUNSEL |
SELL
Open market or private sale
|
Direct |
4,552
-8.81%
|
$27,312
$6.26 P/Share
|
|
May 16
2025
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
13,964
-8.74%
|
$83,784
$6.26 P/Share
|
|
May 15
2025
|
Lauren Merendino Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,536
+9.04%
|
-
|
|
May 15
2025
|
Charles N York Ii COO, CFO AND SECRETARY |
BUY
Exercise of conversion of derivative security
|
Direct |
16,875
+1.57%
|
-
|
|
May 15
2025
|
Adam Dubow GENERAL COUNSEL |
BUY
Exercise of conversion of derivative security
|
Direct |
12,086
+6.02%
|
-
|
|
May 15
2025
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
31,686
+5.03%
|
-
|